clinical trial · NCT02629692
Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies
Healthy (For Part A)Chronic Myeloid Leukemia (for Part B and C)Vodobatinib (K0706) capsules
brief summary
Phase 1/2 study to determine safety, tolerability, pharmacokinetics, and anti-leukemic activity of Vodobatinib (K0706) in treatment-refractory/intolerant CML
started
Jun 27, 2016
primary completion
Aug 1, 2026
completion
Aug 1, 2026
last updated
Jul 31, 2024
detailed description
Part A ( for Healthy volunteers) of the study is completed.
Part B dose-escalation study is completed. Recruitment in dose expansion is completed.
Part C study in subjects with treatment-resistant/intolerant is ongoing for the enrolled subjects.
official title
A Two-Part Phase 1/2 Study to Determine Safety, Tolerability, Pharmacokinetics, and Activity of K0706, a Novel Tyrosine Kinase Inhibitor (TKI), in Healthy Subjects and in Subjects With Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol